Journal of Thrombosis and Thrombolysis

, Volume 29, Issue 4, pp 395–408 | Cite as

Highlights from the II international symposium of thrombosis and anticoagulation (ISTA), October 22–23, 2009, São Paulo, Brazil

  • Renato D. LopesEmail author
  • David Garcia
  • Richard C. Becker
  • Christopher B. Granger
  • L. Kristin Newby
  • John H. Alexander
  • E. Marc Jolicoeur
  • Allison Handler
  • Karen S. Pieper
  • Antonio C. Carvalho
  • Helio P. Guimaraes
  • Dalton A. F. Chamone
  • Antonio C. Baruzzi
  • Fabio S. Machado
  • Ari Timerman
  • Antonio C. Lopes


Thrombosis involving the venous circulatory system, as the proximate cause of deep vein thrombosis (DVT) and pulmonary embolism, and arterial thrombosis responsible for myocardial infarction (MI), ischemic stroke, and sudden cardiac death collectively represent one of the most common, preventable, and treatable disorders in clinical practice.

From a teleological perspective, thrombosis is life-saving and limits blood loss following vascular injury; however, in many ways thrombosis is a very highly evolved and, at times, over-expressed biological response to any breach of vascular integrity or perceived challenge to bodily homeostasis. Accordingly, thrombosis is a well-recognized by-product of infection, trauma, malignancy, and atherosclerosis, as well as several rapidly emerging conditions, including obesity, inactivity, and diabetes mellitus.

The link between aging and both arterial and venous thrombosis is well recognized, spanning all races, nationalities, and cultures....


Atrial Fibrillation Acute Coronary Syndrome Clopidogrel Deep Vein Thrombosis Enoxaparin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The II International Symposium of Thrombosis and Anticoagulation (ISTA) was sponsored by an unrestricted grant from sanofi-aventis. The symposium was organized by Meeting Eventos, and the chairmen of the meeting thank Cecilia Jahnel, Fernanda Prestes, and Daniela Rodrigues for all of their support in the organization of the symposium.


  1. 1.
    Lopes RD, Becker RC, Garcia D, Hylek EM, Granger CB, Lourenço DM, Nader HB, Maffei FH, Cesena FH, Nicolau JC, Timmerman A, Rocha AT, de Paiva EF, Guimaraes HP, Carvalho AC, D’Amico EA, Moreira-Filho CA, Aldrighi JM, Lopes AC (2009) Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23–25, 2008, Sao Paulo, Brazil. J Thromb Thrombolysis 28:106–116CrossRefPubMedGoogle Scholar
  2. 2.
    Heit JA (2008) The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 28:370–372CrossRefPubMedGoogle Scholar
  3. 3.
    Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2007) Universal definition of myocardial infarction. J Am Coll Cardiol 50:2173–2195CrossRefPubMedGoogle Scholar
  4. 4.
    Steg PG, FitzGerald G, Fox KA (2009) Risk stratification in non-ST-segment elevation acute coronary syndromes: troponin alone is not enough. Am J Med 122:107–108CrossRefPubMedGoogle Scholar
  5. 5.
    Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases, Emerging Risk Factors, the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416CrossRefPubMedGoogle Scholar
  6. 6.
    Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A, Intracoronary Stenting Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295:1531–1538CrossRefPubMedGoogle Scholar
  7. 7.
    Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867CrossRefPubMedGoogle Scholar
  8. 8.
    Lopes RD, Alexander KP (2009) Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 104(5 Suppl):16C–21CCrossRefPubMedGoogle Scholar
  9. 9.
    Becker RC (2002) Antithrombotic therapy after myocardial infarction. N Engl J Med 347:1019–1022CrossRefPubMedGoogle Scholar
  10. 10.
    Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG, American College of Chest Physicians (2008) Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: ACCP Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:670S–707SCrossRefPubMedGoogle Scholar
  11. 11.
    Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, American Heart Association, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Pearle DL, Sloan MA, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247CrossRefPubMedGoogle Scholar
  12. 12.
    Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management o Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction), American College of Emergency Physicians, Society for Cardiovascular Angiography, Interventions; Society of Thoracic Surgeons, American Association of Cardiovascular, Pulmonary Rehabilitation, Society for Academic Emergency Medicine (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 50:e1–e157CrossRefPubMedGoogle Scholar
  13. 13.
    APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 119:2877–2885CrossRefPubMedGoogle Scholar
  14. 14.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M (2009) Ticagrelor versus copidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRefPubMedGoogle Scholar
  15. 15.
    Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulant. Blood 115:15–20CrossRefPubMedGoogle Scholar
  16. 16.
    Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH (2008) Antithrombotic therapy in atrial fibrillation—guidelines translated for the clinician. J Thromb Thrombolysis 26:167–174CrossRefPubMedGoogle Scholar
  17. 17.
    Lopes RD, Elliott LE, White HD, Hochman JS, Van Der Werf F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB (2009) Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 30:2019–2028CrossRefPubMedGoogle Scholar
  18. 18.
    Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL, American Heart Association/American Stroke Association Stroke Council, Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group, Cardiovascular Nursing Council; Clinical Cardiology Council, Nutrition, Physical Activity, Metabolism Council, Quality of Care, Outcomes Research Interdisciplinary Working Group, American Academy of Neurology (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 37:1583–1633PubMedGoogle Scholar
  19. 19.
    Sandercock P, Counsell C, Kamal AK (2009) Anticoagulants for acute ischemic stroke. Stroke 40:e483–e484CrossRefGoogle Scholar
  20. 20.
    Engelter ST, Brandt T, Debette S, Caso V, Lichy C, Pezzini A, Abboud S, Bersano A, Dittrich R, Grond-Ginsbach C, Hausser I, Kloss M, Grau AJ, Tatlisumak T, Leys D, Lyrer PA, for the Cervical Artery Dissection in Ischemic Stroke Patients (CADISP) Study Group (2007) Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 38:2605–2611CrossRefPubMedGoogle Scholar
  21. 21.
    Hossain P, Kawar B, El Nahas M (2007) Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 356:213–215CrossRefPubMedGoogle Scholar
  22. 22.
    Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115:708–716CrossRefPubMedGoogle Scholar
  23. 23.
    Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118:1626–1636CrossRefPubMedGoogle Scholar
  24. 24.
    Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, Intracoronary Stenting Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627–3635CrossRefPubMedGoogle Scholar
  25. 25.
    Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26:115–117PubMedGoogle Scholar
  26. 26.
    Hirsch DR, Ingenito EP, Goldhaber SZ (1995) Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 274:335–337CrossRefPubMedGoogle Scholar
  27. 27.
    Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360:1851–1861CrossRefPubMedGoogle Scholar
  28. 28.
    Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr, ENDORSE Investigators (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394CrossRefPubMedGoogle Scholar
  29. 29.
    Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA (2004) The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148:157–164CrossRefPubMedGoogle Scholar
  30. 30.
    Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O’Connor CM, Schulman KA, Teo K, Warren SR, WATCH Trial Investigators (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure. Circulation 119:1616–1624CrossRefPubMedGoogle Scholar
  31. 31.
    Pullicino P, Thompson JL, Barton B, Levin B, Graham S, Freudenberger RS, WARCEF Investigators (2006) Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 12:39–46CrossRefPubMedGoogle Scholar
  32. 32.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:381S–453SCrossRefPubMedGoogle Scholar
  33. 33.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines. J Am Coll Cardiol 53:e1–e90CrossRefPubMedGoogle Scholar
  34. 34.
    Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48:854–906CrossRefPubMedGoogle Scholar
  35. 35.
    ACTIVE Investigators (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360:2066–2078CrossRefGoogle Scholar
  36. 36.
    Connolly S, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis B, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee, Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  37. 37.
    Crowther MA, Warkentin TE (2009) Managing bleeding in anti-coagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 7(Suppl 1):107–110CrossRefPubMedGoogle Scholar
  38. 38.
    Ageno W, Garcia D, Aguilar MI, Douketis J, Finazzi G, Imberti D, Iorio A, Key NS, Lim W, Marietta M, Prisco D, Sarode R, Testa S, Tosetto A, Crowther M (2009) Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol 84:584–588CrossRefPubMedGoogle Scholar
  39. 39.
    Friedman LM, Furberg CD, DeMets DL (1996) Fundamentals of clinical trials, 3rd edn. Mosby-Year Book, Inc., St. LouisGoogle Scholar
  40. 40.
    Pocock SJ (1996) Clinical trials: a practical approach. Wiley, ChichesterGoogle Scholar
  41. 41.
    Bailar JC III, Mosteller F (1988) Guidelines for statistical reporting in articles for medical journals. Ann Intern Med 108:266–273PubMedGoogle Scholar
  42. 42.
    Pieper KS, Tsiatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang WC, Griffin J, Armstrong PW, Califf RM, Harrington RA (2004) Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation 109:641–646CrossRefPubMedGoogle Scholar
  43. 43.
    Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ, American College of Chest Physicians (2008) Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):110S–112SCrossRefPubMedGoogle Scholar
  44. 44.
    Ashrani AA, Heit JA (2009) Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis 28:465–476CrossRefPubMedGoogle Scholar
  45. 45.
    Prandoni P, Kahn SR (2009) Post-thrombotic syndrome: prevalence, prognostication, and need for progress. Br J Haematol 145:286–295CrossRefPubMedGoogle Scholar
  46. 46.
    Fivenson D, Scherschun L (2003) Clinical and economic impact of Apligraf for the treatment of non-healing venous leg ulcers. Int J Dermatol 42:960–965CrossRefPubMedGoogle Scholar
  47. 47.
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907CrossRefPubMedGoogle Scholar
  48. 48.
    Boccaccio C, Comoglio PM (2009) Genetic link between cancer and thrombosis. J Clin Oncol 27:4827–4833CrossRefPubMedGoogle Scholar
  49. 49.
    Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16PubMedGoogle Scholar
  50. 50.
    White R (2003) The epidemiology of venous thromboembolism. Circulation 107(23 suppl 1):I4–I8PubMedGoogle Scholar
  51. 51.
    Fekrazad MH, Lopes RD, Stashenko GJ, Alexander JH, Garcia D (2009) Treatment of venous thromboembolism: guidelines translated for the clinician. J Thromb Thrombolysis 28:270–275CrossRefGoogle Scholar
  52. 52.
    Lopes RD, Ohman EM, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, Crespo EM, Oliveira GB, Moll S, Moliterno DJ, Abrams CS, Becker RC (2009) Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). Am J Cardiol 104:1285–1291CrossRefPubMedGoogle Scholar
  53. 53.
    Jolicoeur EM, Ohman EM, Honeycutt E, Becker RC, Crespo EM, Oliveira GB, Moliterno DJ, Anstrom KJ, Granger CB (2009) Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. Am J Cardiol 104:292–297CrossRefPubMedGoogle Scholar
  54. 54.
    Jolicoeur EM, Wang T, Lopes RD, Ohman EM (2007) Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Curr Cardiol Rep 9:396–405CrossRefPubMedGoogle Scholar
  55. 55.
    Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):340S–380SCrossRefPubMedGoogle Scholar
  56. 56.
    Cook DJ, Crowther MA, Geerts WH (2005) On the need a workshop on venous thromboembolism in critical care. J Crit Care 20:306–308CrossRefPubMedGoogle Scholar
  57. 57.
    Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ, American College of Chest Physicians (2008) Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:71S–109SCrossRefPubMedGoogle Scholar
  58. 58.
    Yusuf S, Bosch J, Devereaux PJ, Collins R, Baigent C, Granger C, Califf R, Temple R (2008) Sensible guidelines for the conduct of large clinical trials. Clin Trials 5:38–39CrossRefPubMedGoogle Scholar
  59. 59.
    Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA (2009) Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360:816–823CrossRefPubMedGoogle Scholar
  60. 60.
    Duke Clinical Research Institute (2009) DCRI: Who we are. Accessed 20 Jan 2010
  61. 61.
    Brazilian Clinical Research Institute (2009) Accessed 20 Jan 2010

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Renato D. Lopes
    • 1
    • 2
    Email author
  • David Garcia
    • 3
  • Richard C. Becker
    • 1
  • Christopher B. Granger
    • 1
  • L. Kristin Newby
    • 1
  • John H. Alexander
    • 1
  • E. Marc Jolicoeur
    • 4
  • Allison Handler
    • 1
  • Karen S. Pieper
    • 1
  • Antonio C. Carvalho
    • 2
  • Helio P. Guimaraes
    • 2
  • Dalton A. F. Chamone
    • 5
  • Antonio C. Baruzzi
    • 6
  • Fabio S. Machado
    • 5
  • Ari Timerman
    • 7
  • Antonio C. Lopes
    • 2
  1. 1.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  2. 2.Paulista School of MedicineFederal University of São PauloSão PauloBrazil
  3. 3.University of New Mexico Health Sciences CenterAlbuquerqueUSA
  4. 4.Montreal Heart InstituteUniversité de MontréalMontrealCanada
  5. 5.São Paulo University Medical SchoolSão PauloBrazil
  6. 6.Albert Einstein HospitalSão PauloBrazil
  7. 7.Dante Pazzanese Institute of CardiologySão PauloBrazil

Personalised recommendations